New Management Kåre Schultz is Named New President & CEO of Teva Pharmaceutical
From carrying out significant strategies to making a mark in the healthcare industry through his experience of 30 years, Kåre Schultz has been appointed as the new face of the company.
Jerusalem/Israel — Teva Pharmaceutical Industries has recently announced that its Board of Directors has named Kåre Schultz to become the company’s President and Chief Executive Officer. Schultz will succeed Dr. Yitzhak Peterburg, who will continue to serve as Interim Chief Executive Officer until Schultz joins the company.
The leadership announcement represents the successful completion of the global search process to identify the best leader for the company and was executed by the Teva Board of Directors, with the assistance of Heidrick & Struggles. Schultz will be relocating to Israel.
Schultz is a seasoned veteran in the healthcare industry with a distinguished, nearly thirty year career across various global pharmaceutical and healthcare companies. Over the course of his career, he has developed a unique perspective overseeing generic and specialty drug portfolios, while managing complex business operations around the world.
He most recently served as the President and Chief Executive Officer of H. Lundbeck A/S, where he is credited with leading significant restructuring initiatives and also launching a robust turnaround strategy focused on driving a sustainable global cost structure and operational model.